Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 25:9:539-544.
doi: 10.2147/CMAR.S142324. eCollection 2017.

High expression of eIF3d is associated with poor prognosis in patients with gastric cancer

Jiaqi He  1 , Xuefei Wang  2 , Jianhua Cai  1 , Wei Wang  1 , Xinyu Qin  2
Affiliations

High expression of eIF3d is associated with poor prognosis in patients with gastric cancer

Jiaqi He et al. Cancer Manag Res. .

Abstract

Background: Eukaryotic initiation factor 3 subunit d (eIF3d) is the largest subunit of eIF3, which is shown to promote protein synthesis in cancer cells. Increased expression of eIF3d has been shown in some types of cancers, but has not been previously studied in gastric cancer (GC). Thus, the aim of this study was to analyze eIF3d expression in GC.

Patients and methods: Expression of eIF3d was detected by immunohistochemistry in GC tissues and adjacent noncancerous (ANC) tissues. Samples were obtained from 210 patients with GC who had received curative gastrectomy. Clinicopathological features and survival rate were also analyzed.

Results: Expression rates of eIF3d in GC and ANC were 45.2% and 21.0%, respectively. High expression of eIF3d protein was significantly related to tumor stage, as determined by lymph node metastasis and depth of invasion (p<0.05). The Kaplan-Meier survival curves showed that patients with high eIF3d expression had a significantly poor overall survival (p=0.005). Multivariate Cox regression analyses showed that the level of eIF3d was an independent predictive factor of poor prognosis for GC (p=0.017).

Conclusion: Expression of eIF3d was upregulated in GC. High expression of eIF3d was determined as an independent poor prognostic factor in GC. It is suggested that eIF3d could be a good biomarker in GC.

Keywords: biomarker; eIF3d; eukaryotic translation initiation factors 3d; gastric cancer; prognosis.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
The expression of eIF3d in gastric cancer tissues and adjacent noncancerous tissues. Notes: (A) High eIF3d expression in gastric cancer tissues. (B) Low eIF3d expression in gastric cancer tissues. (C) Negative eIF3d expression in adjacent noncancerous tissues. Magnification ×20. Abbreviation: eIF3d, eukaryotic initiation factor 3 subunit d.
Figure 2
Figure 2
Kaplan–Meier analysis for overall survival of patients with gastric cancer according to eIF3d expression. Notes: (A) The overall survival in all patients. (B) The overall survival in patients with TNM I stage. (C) The overall survival in patients with TNM II stage. (D) The overall survival in patients with TNM III stage. Abbreviations: Cum, cumulative; eIF3d, eukaryotic initiation factor 3 subunit d.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. - PubMed
    1. Yoon H, Kim N. Diagnosis and management of high risk group for gastric cancer. Gut Liver. 2015;9(1):5–17. - PMC - PubMed
    1. Lim L, Michael M, Mann GB, Leong T. Adjuvant therapy in gastric cancer. J Clin Oncol. 2005;23(25):6220–6232. - PubMed
    1. Stock M, Otto F. Gene deregulation in gastric cancer. Gene. 2005;360(1):1–19. - PubMed
    1. Damoc E, Fraser CS, Zhou M, et al. Structural characterization of the human eukaryotic initiation factor 3 protein complex by mass spectrometry. Mol Cell Proteomics. 2007;6(7):1135–1146. - PubMed

LinkOut - more resources